Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.37% to $477.52 Monday, on what proved to be an all-around dismal trading ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

Vertex’s stock price has shown remarkable growth ... on revenue of $175.0 million to $178.0 million. InvestingPro analysis reveals the company maintains a healthy financial profile with an ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, ...

With a current market capitalization of $121 billion and analyst targets ranging from $330 to $591, InvestingPro analysis suggests the stock is currently trading near its Fair Value. Vertex ...

Vertex Pharmaceuticals (NASDAQ ... According to InvestingPro analysis, the stock is currently trading above its Fair Value, with a high EBITDA multiple of 25.5x reflecting investor optimism ...

Morgan Stanley lowered the firm’s price target on Vertex (VERX) to $55 from $60 and keeps an Overweight rating on the shares. The firm is ...

Vertex Software's stock has fallen ~30% since January due to a valuation correction and market pessimism over slowing growth rates. Despite the selloff, Vertex's valuation multiples haven't ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $51.3, a high estimate of $61.00, and a low estimate of $31.00. A 14.64% drop is evident in the current ...

Vertex’s stock price has shown remarkable growth ... of $33.0 million to $37.0 million on revenue of $175.0 million to $178.0 million. InvestingPro analysis reveals the company maintains a healthy ...

Vertex Pharmaceuticals (NASDAQ ... gaining nearly 25% year-to-date and trading near its 52-week high of $519.88. According to InvestingPro analysis, the stock is currently trading above its Fair Value ...